Stingthera, Inc. announced it has entered into a clinical trial collaboration agreement with Merck to evaluate the combination of SNX281, Stingthera’s investigational small molecule activator of the Stimulator of Interferon Genes (STING) protein, and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors and lymphoma who have relapsed on or have become refractory to prior immune checkpoint therapy.
The clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SNX281 as a monotherapy and in combination with KEYTRUDA, Merck’s anti-PD-1 (anti-programmed death receptor-1) therapy, in patients with advanced solid tumors and lymphoma who have relapsed on or have become refractory to prior immune checkpoint therapy. After determination of the optimal dose of SNX281 as a single-agent and in combination with KEYTRUDA, expansion cohorts to further evaluate safety and efficacy in specific populations will be examined. This includes colorectal and ovarian cancer in the monotherapy arm and refractory or relapsed tumors on checkpoint inhibitors in the combination arm. For more information about the SNX281 clinical trial (NCT04609579), please visit: https://clinicaltrials.gov.
"We are pleased to collaborate with Merck to evaluate SNX281 in combination with KEYTRUDA as treatment for people with solid tumors or lymphoma who have relapsed on or have become refractory to prior immune checkpoint therapy, as these are patients for which there are limited treatment options available and their overall survival remains low," said Humphrey Gardner, M.D., F.C.A.P., chief medical officer, Stingthera. "We look forward to further evaluating the potential clinical utility of this combination, in an effort to improve outcomes for patients with a number of different cancers.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!